Cardiovascular complications of chimeric antigen receptor (CAR)-t cell therapy: insights from a regional cardio-oncology program

View Full Paper

Ask AI

Bookmark

Thirty percent of patients undergoing car-t therapy developed cardiovascular complications.
Patients with cytokine release syndrome had significantly lower left ventricular ejection fraction.
Pre-treatment cardiac evaluations can identify high-risk individuals for cardiac events.
All patients with adverse cardiac outcomes recovered before discharge despite severe initial complications.

Discussion

No takes yet. Share an insight, caveat, or question.

This observational analysis evaluates cardiovascular risks in patients undergoing CAR-T therapy, indicating the need for cardio-oncology management.

Guerra et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This observational analysis evaluates cardiovascular risks in patients undergoing CAR-T therapy, indicating the need for cardio-oncology management.